Janux Therapeutics Inc (JANX) Stock Price, Quote & News

Company Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 751 4493

Website: www.januxrx.com

Address:

10955 Vista Sorrento Parkway, Suite 200, San Diego, United States

Cracker36 Jan. 16 at 7:45 PM

$JANX look like I'll be buying my 1800 call shares for 12.50...... thanks :))

1 · Reply

Ashantifinancial45 Jan. 16 at 10:03 AM

$JANX ....This ✔️

0 · Reply

Cheaslea76 Jan. 15 at 6:09 PM

$JANX $10

0 · Reply

ilestz Jan. 15 at 5:01 PM

$JANX nothing will change until those friday options expire…

2 · Reply

dddanielek Jan. 15 at 3:28 PM

$JANX trying to activate stop loses. Same tactic every few days on low volume days

0 · Reply

dddanielek Jan. 15 at 3:27 PM

$JANX short attack this morning. Hold on to your shares.

0 · Reply

aletz Jan. 15 at 9:17 AM

$JANX Adios a $13, never again!

1 · Reply

Kevinb511 Jan. 14 at 9:48 PM

$JANX nice to close green

0 · Reply

OneSmartBull Jan. 14 at 5:52 PM

$JANX a small‑cap immuno‑oncology biotech developing TRACTr and TRACIr T‑cell engager platforms—an area that tends to move sharply. https://investors.januxrx.com/investor-media/news/default.aspx

0 · Reply

OneSmartBull Jan. 14 at 5:44 PM

$JANX looks primed for bullish action

1 · Reply

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Dec 2, 2025, 10:58 AM EST - 6 weeks ago

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Dec 2, 2025, 10:50 AM EST - 6 weeks ago

Janux dives as gaps in prostate cancer study data worry investors

Dec 2, 2025, 8:41 AM EST - 6 weeks ago

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

BWLP SIG

Dec 2, 2025, 8:30 AM EST - 6 weeks ago

Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Dec 1, 2025, 11:13 PM EST - 6 weeks ago

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Dec 1, 2025, 4:05 PM EST - 6 weeks ago

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Nov 24, 2025, 8:00 AM EST - 7 weeks ago

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

Nov 6, 2025, 4:01 PM EST - 2 months ago

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:01 PM EDT - 5 months ago

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 4:05 PM EDT - 5 months ago

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

Jul 31, 2025, 12:01 AM EDT - 6 months ago

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Jul 24, 2025, 4:05 PM EDT - 6 months ago

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Jul 17, 2025, 4:30 PM EDT - 6 months ago

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

May 15, 2025, 8:00 AM EDT - 8 months ago

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

May 8, 2025, 4:01 PM EDT - 9 months ago

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 5, 2025, 8:30 AM EDT - 9 months ago

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Apr 5, 2025, 8:14 AM EDT - 10 months ago

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Feb 27, 2025, 4:01 PM EST - 11 months ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Jan 24, 2025, 4:01 PM EST - 1 year ago

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Jan 8, 2025, 9:00 AM EST - 1 year ago

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Jan 2, 2025, 11:46 PM EST - 1 year ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD LUNR MSTR

Dec 6, 2024, 7:43 PM EST - 1 year ago

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Dec 4, 2024, 11:12 PM EST - 1 year ago

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Dec 3, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Announces Proposed Public Offering

Dec 3, 2024, 10:49 AM EST - 1 year ago

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Dec 3, 2024, 10:39 AM EST - 1 year ago

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Dec 2, 2024, 4:30 PM EST - 1 year ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Nov 25, 2024, 9:00 AM EST - 1 year ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Nov 19, 2024, 1:23 AM EST - 1 year ago

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Nov 6, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 22, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Announces Updates to Board of Directors

Jun 26, 2024, 8:32 AM EDT - 1 year ago

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

May 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 30, 2024, 12:06 AM EDT - 1 year ago

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Apr 11, 2024, 9:00 AM EDT - 1 year ago

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT VKTX AMLX MCRB RAPT RVNC

Mar 20, 2024, 1:44 PM EDT - 1 year ago

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Mar 8, 2024, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 29, 2024, 1:22 AM EST - 2 years ago

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Feb 27, 2024, 5:15 PM EST - 2 years ago

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27, 2024, 5:00 PM EST - 2 years ago

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Feb 27, 2024, 8:38 AM EST - 2 years ago

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Feb 26, 2024, 4:05 PM EST - 2 years ago

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Feb 20, 2024, 8:00 AM EST - 2 years ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

Jan 8, 2024, 9:00 AM EST - 2 years ago

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

Nov 7, 2023, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 17, 2023, 8:45 AM EDT - 2 years ago

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Cracker36 Jan. 16 at 7:45 PM

$JANX look like I'll be buying my 1800 call shares for 12.50...... thanks :))

1 · Reply

Ashantifinancial45 Jan. 16 at 10:03 AM

$JANX ....This ✔️

0 · Reply

Cheaslea76 Jan. 15 at 6:09 PM

$JANX $10

0 · Reply

ilestz Jan. 15 at 5:01 PM

$JANX nothing will change until those friday options expire…

2 · Reply

dddanielek Jan. 15 at 3:28 PM

$JANX trying to activate stop loses. Same tactic every few days on low volume days

0 · Reply

dddanielek Jan. 15 at 3:27 PM

$JANX short attack this morning. Hold on to your shares.

0 · Reply

aletz Jan. 15 at 9:17 AM

$JANX Adios a $13, never again!

1 · Reply

Kevinb511 Jan. 14 at 9:48 PM

$JANX nice to close green

0 · Reply

OneSmartBull Jan. 14 at 5:52 PM

0 · Reply

OneSmartBull Jan. 14 at 5:44 PM

$JANX looks primed for bullish action

1 · Reply

theobill325 Jan. 14 at 5:34 PM

$JANX keep going to the right direction 👏 👌 🙌

0 · Reply

aletz Jan. 13 at 8:04 PM

$JANX averaged down to $14.4

1 · Reply

aletz Jan. 13 at 7:50 PM

$JANX https://www.biospace.com/business/jpm26-confident-merck-sees-growth-through-keytruda-loss-of-exclusivity Merck, JANX is at discount now!!

0 · Reply

fantastex Jan. 13 at 12:37 PM

$JANX 13.50 retest then up or $13 test

0 · Reply

theobill325 Jan. 13 at 12:29 PM

$JANX im telling you it will be above 15 before eow!!!

0 · Reply

Softclothes Jan. 13 at 7:04 AM

$JANX increase of almost 2 million shares in short interest and not a large drop in price to show for it. Looks like absorption at this level.

1 · Reply

Peterson28 Jan. 12 at 10:28 PM

$JANX Chart is telling me this is bottoming out

1 · Reply

MarketWarfare Jan. 12 at 8:57 PM

$JANX 2nd worst performing biotech in the past year out of 215 companies, minimum value 500M. Unacceptable. Only srpt has been a larger piece of shit, and it still trades at nearly 3x cash value. This CEO needs to go immediately. Inept turd.

1 · Reply

Captenotwo Jan. 12 at 8:29 PM

$JANX I have to admit it’s kids F’d there’s no update on 008 Let’s go already!!! Frustrated Cap

0 · Reply

Swice24 Jan. 12 at 5:15 PM

$JANX time to get going up!!

0 · Reply

Suhair1977 Jan. 12 at 3:36 PM

$JANX Short sellers getting rich while management probably getting greased off them.

0 · Reply

Ashantifinancial45 Jan. 11 at 7:31 PM

$JANX ....Extreme punishment....Cam we get 16 tomorrow

0 · Reply

Market Cap	849.29M
Revenue (ttm)	10.59M
Net Income (ttm)	-68.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-651.46%
Debt to Equity Ratio	0.00

Volume	1,757,600
Avg Vol	2,115,348
Day's Range	N/A - N/A
Shares Out	60.15M
Stochastic %K	43%
Beta	2.88
Analysts	Strong Sell
Price Target	$60.53